Eli Lilly COVID-19 antibody drug shipments paused over variant considerations

U.S. well being officers have paused the distribution of two Eli Lilly & Co.

Covid-19 monoclonal antibody therapies due to information displaying they aren’t efficient in opposition to virus variants which can be changing into more and more frequent throughout the nation.

The Division of Well being and Human Providers stated Friday that it’s instantly pausing all distribution of bamlanivimab and etesevimab collectively, in addition to etesevimab alone to be paired with current provides of bamlanivimab, within the U.S. till additional discover.

An expanded version of this article appears on WSJ.com.

Fashionable tales from WSJ.com:

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *